109 related articles for article (PubMed ID: 2532749)
1. BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion.
Smith EF; Earl CQ; Egan JW
Prostaglandins Leukot Essent Fatty Acids; 1989 Oct; 38(1):15-23. PubMed ID: 2532749
[TBL] [Abstract][Full Text] [Related]
2. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
Smith EF; Griswold DE; Egan JW; Hillegass LM; DiMartino MJ
J Cardiovasc Pharmacol; 1989 May; 13(5):715-22. PubMed ID: 2472519
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of antagonism of thromboxane receptors in vascular smooth muscle.
Yanagisawa A; Smith JA; Brezinski ME; Lefer AM
Eur J Pharmacol; 1987 Jan; 133(1):89-96. PubMed ID: 3030773
[TBL] [Abstract][Full Text] [Related]
4. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective actions of thromboxane receptor antagonism in ischemic atherosclerotic rabbits.
Osborne JA; Lefer AM
Am J Physiol; 1988 Aug; 255(2 Pt 2):H318-24. PubMed ID: 2970233
[TBL] [Abstract][Full Text] [Related]
6. Daltroban, a thromboxane receptor antagonist, protects the myocardium against reperfusion injury following myocardial ischemia without protecting the coronary endothelium.
Viehman GE; Ma XL; Lefer AM
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):651-6. PubMed ID: 1966110
[TBL] [Abstract][Full Text] [Related]
7. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
Grover GJ; Schumacher WA; Simon M; Parham C
J Cardiovasc Pharmacol; 1988 Dec; 12(6):701-9. PubMed ID: 2467089
[TBL] [Abstract][Full Text] [Related]
8. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
Griswold DE; Egan JW; Earl CQ; Hillegass LM; Marshall PJ; Smith EF
Prog Clin Biol Res; 1989; 301():161-5. PubMed ID: 2529547
[No Abstract] [Full Text] [Related]
9. Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve.
Grover GJ; Schumacher WA
J Pharmacol Exp Ther; 1989 Feb; 248(2):484-91. PubMed ID: 2521899
[TBL] [Abstract][Full Text] [Related]
10. Effect of thromboxane receptor antagonists on venous thrombosis in rats.
Schumacher WA; Heran CL
J Pharmacol Exp Ther; 1989 Mar; 248(3):1109-15. PubMed ID: 2522985
[TBL] [Abstract][Full Text] [Related]
11. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
[TBL] [Abstract][Full Text] [Related]
12. Effect of the thromboxane receptor antagonist SQ 29,548 on myocardial infarct size in dogs.
Grover GJ; Schumacher WA
J Cardiovasc Pharmacol; 1988 Jan; 11(1):29-35. PubMed ID: 2450253
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of a new specific thromboxane antagonist in arachidonate-induced sudden death.
Lefer DJ; Mentley RK; Lefer AM
Arch Int Pharmacodyn Ther; 1987 May; 287(1):89-95. PubMed ID: 2957969
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats.
Bhat AM; Sacks H; Osborne JA; Lefer AM
Am Heart J; 1989 Apr; 117(4):799-803. PubMed ID: 2929397
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of a novel thromboxane antagonist, BAY-U3405, on canine myocardial damage after coronary artery occlusion and reperfusion.
Fiedler VB; Perzborn E; Seuter F
Pharmacotherapy; 1991; 11(1):77-84. PubMed ID: 2020615
[TBL] [Abstract][Full Text] [Related]
16. Anti-ischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats.
Brezinski ME; Yanagisawa A; Darius H; Lefer AM
Am Heart J; 1985 Dec; 110(6):1161-7. PubMed ID: 3000159
[TBL] [Abstract][Full Text] [Related]
17. Effect of the thromboxane receptor antagonist, BM 13.505, on the sequelae of endotoxemia in the conscious rat.
Smith EF; Jugus M; Kinter LB
Eicosanoids; 1988; 1(1):27-33. PubMed ID: 3078574
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
Olson RW; Dotson R; Mathis J; Cohen DS; Webb RL
Eur J Pharmacol; 1993 May; 236(1):75-87. PubMed ID: 8319746
[TBL] [Abstract][Full Text] [Related]
19. Effect of propranolol on ischemic myocardial damage and left ventricular hypertrophy following permanent coronary artery occlusion or occlusion followed by reperfusion.
Smith EF; Egan JW; Griswold DE
Pharmacology; 1989; 38(5):298-309. PubMed ID: 2527373
[TBL] [Abstract][Full Text] [Related]
20. The thromboxane receptor antagonist, daltroban, protects the myocardium from ischaemic injury resulting in suppression of leukocytosis.
Thiemermann C; Ney P; Schrör K
Eur J Pharmacol; 1988 Oct; 155(1-2):57-67. PubMed ID: 2977337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
